Senator Ron Johnson Launches Investigation Into FDA Rare Disease Drug Denials
Senator Ron Johnson (R-Wis.) has initiated a formal investigation into the FDA's handling of biologic therapy applications for rare diseases, specifically targeting Duchenne muscular dystrophy. The probe follows a direct consultation with FDA Commissioner Marty Makary regarding perceived regulatory barriers for life-saving treatments.